Oral NINLARO is administered once a week for 3 weeks of a 4‑week cycle1
The usual recommended starting dose of NINLARO is one 4 mg capsule taken once a week based on the following schedule:1
- The recommended starting dose of oral NINLARO is 3 mg for patients with moderate or severe hepatic impairment, severe renal impairment or end-stage renal disease requiring dialysis1
NINLARO should be taken with lenalidomide and dexamethasone at standard dosing1
- The recommended starting dose of lenalidomide is 25 mg administered daily on days 1 to 21 of a 28‑day treatment cycle
- The recommended starting dose of dexamethasone is 40 mg administered on days 1, 8, 15, and 22 of a 28‑day treatment cycle
Prior to initiating a new cycle of therapy:1
- Absolute neutrophil count should be ≥1000/mm3
- Platelet count should be ≥75,000/mm3
- Non-haematological toxicities should, at the physician's discretion, generally be recovered to patient's baseline condition or Grade ≤1
- Treatment should be continued until disease progression or unacceptable toxicity†
- Antiviral prophylaxis should be considered to reduce the risk of herpes zoster reactivation
- For additional information regarding lenalidomide or dexamethasone, please refer to each respective SmPC
† Treatment with NINLARO in combination with lenalidomide and dexamethasone for longer than 24 cycles should be based on an individual benefit risk assessment1
NINLARO Patient Support Programme (PSP)
This NINLARO Patient Support Programme (PSP) has been designed to help patients familiarise themselves with the NINLARO based triplet regimen. The programme is intended for patients that are currently receiving or are about to initiate treatment with the NINLARO regimen.
To download a copy of the booklet, which provides further information on the programme for Healthcare Professional click here
- NINLARO (ixazomib capsules) Summary of Product Characteristics.
- Moreau P, Masszi T, Grzasko N. N Engl J Med. 2016;374:1621-34.
- REVLIMID 25 mg Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/29490.
- Takeda Data on File - UK/DF/1701/0001.
- Takeda Data on File - UK/DF/1611/0018.
- Protocol for Moreau P, Masszi T, Grzasko N. N Engl J Med. 2016;374:1621-34.